Connection

Andrea Antinori to Reverse Transcriptase Inhibitors

Back to Details
This is a "connection" page, showing publications Andrea Antinori has written about Reverse Transcriptase Inhibitors.
Andrea Antinori
Connection Strength
0.872
Reverse Transcriptase Inhibitors
  1. COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. J Med Virol. 2021 03; 93(3):1796-1804.
    View in: PubMed
    Score: 0.186
  2. Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents. 2019 Apr; 53(4):515-519.
    View in: PubMed
    Score: 0.166
  3. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59.
    View in: PubMed
    Score: 0.163
  4. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Med. 2018 05 29; 16(1):79.
    View in: PubMed
    Score: 0.158
  5. Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clin Trials. 2018 04; 19(2):52-60.
    View in: PubMed
    Score: 0.155
  6. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. J Antimicrob Chemother. 2019 11 01; 74(11):3295-3304.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.